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cal laboratories to differentiate Streptococcus pneumoniae
(Pneumococci) from other -heamolytic streptococci. How-
ever, presence of optochin resistant pneumococci may lead
to misidentiﬁcation that will cause a compromise with treat-
ment and prevention of pneumococcal diseases. The typical
optochin susceptibility of Pneumococci resides in the Fo
complex of its FoF1 H+-ATPase, an ion transport enzyme that
is essential for the viability of this organism. Mechanism of
optochin resistance has been attributed to a single point
mutation in amino acid residues of the H+-ATPase c-subunit
(atpC).
Objective: To validate the preserved isolates and iden-
tify optochin-resistant pneumococci by bile solubility test
and PCR for lytA gene and to determine the mechanism of
optochin resistance.
Methodology: Alpha hemolytic streptococci isolated from
4,730 nasopharyngeal swabs of children <5 years old. The
isolates were validated by colony morphology, optochin sus-
ceptibility, bile solubility, PCR for lyt A (autolysin) and
ATPase c-subunit genes and sequencing to detect any AA
mutations.
Results: In total, 1618 -haemolytic isolates were vali-
dated; 111(6.86%) were Optr -heamolytic strains and only
37 (0.8%) were pneumococcus that were bile soluble and
possessed lytA gene. The PCR of atpC from all 37 strains
showed the presence of F0 complex in F0F1 H+-ATPase.
Sequencing of atpC gene of three strains when compared
with reference strain (opts strain R6) revealed the presence
of nucleotide change that produces AA substitution in ATPase
c-subunit protein.
Conclusion: Optochin resistant Streptococcus pneumo-
niae was ﬁrst observed in Bangladesh. A single point
mutation in H+-ATPase c-subunit gene that contributed for
Optr phenotype. Reporting of Opt pneumococci as viridans
streptococcus might have signiﬁcant implications for the
treatment and outcome of patients. Therefore, validation of
-haemolytic streptococci as pneumococci by bile solubility
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Background: Recent years have seen the emergence of
methicillin-resistant Staphylococcus aureus (MRSA) strains
often characterised by community acquisition, unusual
susceptibility to antimicrobials, and the Panton-Valentine
leukocidin (PVL) virulence factor. The epidemiology of these
strains varies between geographical locations. This study
aimed to determine the occurrence and clinical features
of such strains in the University of Malaya Medical Centre,
Kuala Lumpur.
Methods: Laboratory records were examined for MRSA
isolates from 2002—2007. Using CLSI disc diffusion stan-
dards, multisensitive MRSA was deﬁned as susceptibility to
erythromycin, clindamycin, fusidic acid, rifampicin, gen-
tamicin, ciproﬂoxacin, cotrimoxazole, and tetracycline. PCR
detection of mecA and PVL genes lukS-PV-lukF-PV, SCCmec
typing, and MLST were carried out. The PVL product was
conﬁrmed by sequencing. Only cases with isolates avail-
able for PCR conﬁrmation were included in clinical records
review. Centers for Diseases Control and Prevention crite-
ria were used to distinguish between community-associated
(CA-MRSA) and healthcare-associated MRSA.
Results: Multisensitive MRSA from 13 distinct patient-
episodes were identiﬁed; 1 in 2003, 2 in 2006, and 10 in 2007
(0.27%, 0.62%, and 3.1% of new MRSA cases, respectively). 9
isolates from 2007 were available for mecA conﬁrmation. Of
these, only 2 were PVL-positive CA-MRSA; the remaining 7
were healthcare-associated, of which 3 were PVL-positive.
All isolates were of SCCmec type IV. There were 3 isolates of
each sequence type (ST) ST30 and ST6, 1 ST22 strain, and 2
untypeable isolates. Clinical presentations included skin or
soft-tissue infections (6), probable colonisation (2 babies),
bacteraemia (1), and no deaths. All 4 isolates unavailable
for conﬁrmation were healthcare-associated.
Conclusion: We describe the ﬁrst conﬁrmed clinical infec-
tions with multisensitive, SCCmec type IV, PVL-positive MRSA
in Malaysia, which were mainly skin or soft-tissue infections.
In view of the predominance of healthcare-associated acqui-
sition, and the apparent increase in cases in 2007 (albeit
small numbers), further work including multilocus sequence
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Background: Daptomycin is a cyclic lipopeptide approved
for the treatment of complicated skin and soft tissue infec-
tions (cSSTI), right sided infective endocarditis (RIE) due to
Staphylococcus aureus (SA) and for SA bacteraemia when
associated with RIE or with cSSTI. We evaluated the activ-
ity of daptomycin and comparator agents tested against
multidrug-resistant (MDR) Gram-positive organisms isolated
in European hospitals.
Methods: 23,269 Gram-positive organisms were col-
lected through the Daptomycin Surveillance Program in
the 2003—2007 period, including SA (11,836), coagulase-
negative staphylococci (CoNS; 4,445), enterococci (4,464),
viridians group streptococci (VGS; 756) and beta-haemolytic
streptococci (BHS; 1,768). Isolates were consecutively col-
lected from patients with documented infections in 32
European hospitals (14 countries) and susceptibility tested
by CLSI broth microdilution methods against daptomycin and
>20 comparators. Mueller-Hinton broth was supplemented
to a 50mg/L calcium concentration for testing daptomycin.
MDR was deﬁned as resistance to drugs in 3 or more antimi-
crobial classes.
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Results: Only 1 of 11,836 (0.01%) SA strains exhibited non-
susceptibility to daptomycin (MIC, 2mg/L), and resistance to
oxacillin or other antimicrobials did not adversely inﬂuence
daptomycin activity. Daptomycin was active against ente-
rococci (100.0% susceptible), including strains resistant to
vancomycin. Vancomycin-resistant E. faecium increased in
Europe from 12.0% in 2004 to 25.8% in 2007 and varied signiﬁ-
cantly by country. Only 72.1% of E. faecium were susceptible
to quinupristin/dalfopristin. All VGS strains resistant to
penicillin and/or clindamycin and/or levoﬂoxacin were
susceptible to daptomycin. CoNS (MIC90, 0.5mg/L) and
BHS (MIC 90, 0.25mg/L) were also very susceptible to
daptomycin.
Conclusions: Daptomycin displayed signiﬁcant potency
and a wide spectrum of activity against problematic clin-
ical isolates of Gram-positive cocci causing nosocomial
infections in European hospitals, including MDR subsets.
Daptomycin activity remained stable over the 5 year period
evaluated and resistance to other antimicrobial classes did
not adversely affect the high daptomycin activity.
doi:10.1016/j.ijid.2008.05.708
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Background: We determined the in vitro antimicrobial
susceptibilities of Bacillus anthracis isolated in Korea in
order to expand the choices for effective antimicrobial
treatment.
Methods: Sixteen antimicrobials were tested against
92 isolates of the Bacillus cereus group including 69 B.
anthracis, 20 B. cereus and 3 B. mycoides to determine their
MICs, MIC ranges, MIC50s and MIC90s with Etest strips(AB
BIODISK, Solna, Sweden), and broth microdilution method
at 37 ◦C for 24 h.
Results: The results for the 69 B. anthracis isolates
obtained by the broth microdilution method were com-
pared to those generated by the Etest agar gradient
diffusion method. In the Etest agar gradient method, 14.5%
of B. anthracis showed resistance to -lactam antimic-
tobial agents including penicillin (MIC, ≤0.5g/ml) while
91.3% of isolates were intermediate to ceftriaxone (MIC,
>32g/ml) and chloramphenicol (MIC, ≤3 to 4g/ml).
However, in the broth microdilution method, 21.7% of B.
anthracis(MIC, ≤0.5g/ml) showed resistance to penicillin
and intermediate to ceftriaxone (1.4%) and chlorampheni-
col (92.8%). All B. anthracis isolates were susceptible to
amikacin, cephalothin, ciproﬂoxacin, doxycycline, gentam-
icin, kanamycin, rifampicin, streptomycin, tetracycline, and
vancomycin. However, the majority of the B. cereus and
all of the B. mycoides were resistant to the amoxicillin,
ampicillin and penicillin. All B. cereus were susceptible to
amikacin, ciproﬂoxacin, gentamicin, kanamycin and strep-
tomycin.
Conclusion: This study was to examine therapeutic or
prophylactic antimicrobials potentially effective against B.
cereus group isolates using two testing methods.
doi:10.1016/j.ijid.2008.05.709
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Background: Vancomycin is one of the antibiotics
against methicillin-resistant Staphylococcus aureus (MRSA).
Among pharmacokinetic-pharmacodynamic (PK-PD) param-
eters for vancomycin, the ratio of area under the serum
concentration-time curve (AUC) to minimum inhibitory con-
centration (MIC), AUC/MIC, has been considered to be
correlated to efﬁcacy, although Cmin/MIC has been consid-
ered to be correlated to nephrotoxicity. However, there have
been few clinical studies about the relationship of these PK
parameters with clinical efﬁcacy or nephrotoxicity in MRSA
bacteremia.
Methods: From April 2003 to March 2007, all the patients
aged >20 years whose blood cultures were positive for MRSA
at the University of Tokyo Hospital were selected, and the
patients treated with vancomycin alone were enrolled in this
study. A retrospective chart review was performed to col-
lect demographics. AUC/MIC and Cmin/MIC were assumed
by a two-compartment infusion model by VCM-TDM Edition
on Excel Ver.3.0x (provided by Shionogi Co., Osaka, Japan).
Clinical response was deﬁned as resolution of fever, leukocy-
tosis, and reduction of 30% or more of maximum C-reactive
protein on seven days after the onset of bacteremia. Nephro-
toxicity was deﬁned as an increase of 0.5mg/dl or 50% or
more of baseline serum creatine level at the end of van-
comycin treatment. Relationships of AUC/MIC with clinical
response and Cmin/MIC with nephrotoxicity were analyzed.
Results: Average AUC/MIC in good-responders (n = 15)
was not statistically different from that in poor-responders
(n = 16) (384.2± 124.6 vs. 407.6± 172.0, p = 0.66). Average
Cmin/MIC in patients with vancomycin nephrotoxicity was
higher than that in patients without vancomycin nephro-
toxicity, although not statistically different (11.2± 3.1 vs.
9.4± 3.7, p = 0.37).
Conclusion: PK parameters for vancomycin were not cor-
related with clinical efﬁcacy and nephrotoxicity in patients
with MRSA bacteremia. However, further studies are needed
to elucidate the signiﬁcance of the PK parameters, since the
number of the patients enrolled in this study was small.
doi:10.1016/j.ijid.2008.05.710
